Hikma Pharmaceuticals raises guidance as first-half profit jumps 43%

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday increased its interim dividend following ...

Alliance News 8 August, 2024 | 10:33AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday increased its interim dividend following double-digit growth across the business in the first half.

The London-based pharmaceutical company said pretax profit jumped 43% to GBP288 million in the first half that ended June 30 from GBP202 million in the previous year.

Revenue increased 10% to GBP1.57 billion from GBP1.43 billion, while cost of sales grew 14% to GBP813 million from GBP712 million.

Hikma raised it interim dividend by 28% to 32 US cents per share from 25 cents.

Total operating expenses reduced 14% to GBP405 million from GBP470 million.

Chief Executive Officer Riad Mishlawi: "All of our businesses contributed to our strong performance, delivering 10% group revenue growth. We launched new products across all regions, entered new markets in Europe, and further strengthened our leadership team."

Over the six months to June 30, net debt increased 7.1% to USD1.28 billion from USD1.19 billion.

Capital expenditure in the half stood at USD69 million, down 18% from USD84 million last year.

Hikma allocated USD19 million towards upgrades and capacity expansion in the US. Elsewhere, in the Middle East & North Africa and Europe, the company invested USD32 million and USD18 million to strengthen manufacturing capabilties.

By year's end, total capital expenditure is expected between USD140 million to USD160 milion compared to USD169 million in 2023.

Furthermore, in June the company announced the acquisition of parts of the US finished dosage form business from Xellia Pharmaceuticals AS for USD135 million, plus a contingent consideration of up to USD50 million.

The transaction will add marketed products, pipeline projects, extensive manufacturing capabilities, and a new research and development centre for the Injectables business.

Looking ahead, Hikma revised guidance for the full-year and now expects revenue growth to be between 6% to 8%, up from 4% to 6%.

Core operating profit is forecast to be within a USD700 million to USD730 million range, up from USD660 million from USD700 million.

In 2023, Hikma delivered 14% year-on-year revenue growth and a core operating profit of GBP707 million.

Hikma Pharmaceuticals shares were up 6.4% to 1,958.25 pence each in London on Thursday morning.

By Elijah Dale, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Hikma Pharmaceuticals PLC 1,989.62 GBX 8.13 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures